This series on “Radiotherapy for Brain Metastases from Lung Cancer” is edited by Prof. Lucyna Kepka from the Department of radiotherapy, Miitary Institute of Medicine, Warsaw, Poland.
All aforementioned considerations relate to the patients with preserved performance status who may benefit from the progress in the management of lung cancer. However, among patients with brain metastases from lung cancer, there is a significant proportion of patients with poor performance status, for whom WBRT has no benefit over the use of steroids alone. These patients should benefit from the early introduction of all measures of palliative care without radiotherapy, because such an approach improves the quality of life, especially in patients with lung cancer.
Treatment of brain metastases from lung cancer: challenging the historical nihilism concerning prognosis
Hippocampal avoidance in prophylactic cranial irradiation for small cell lung cancer: benefits and pitfalls
WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view
Radiotherapy for brain metastases from small-cell lung cancer in distinct clinical indications and scenarios
Local ablative therapy of brain metastasis from non-small cell lung cancer: benefits and limitations
The focused issue “Radiotherapy for Brain Metastases from Lung Cancer” was commissioned by the editorial office, Journal of Thoracic Disease without any funding or sponsorship. Lucyna Kepka is serving as the unpaid Guest Editor for the focused issue.